上海
分享至
礼来当地时间4月1日宣布，其口服小分子GLP-1受体激动剂Orforglipron已获得美国FDA批准上市，用于治疗成人肥胖或超重。
特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
